Teligent, Inc. (TLGT) Expected to Announce Quarterly Sales of $19.17 Million
Analysts predict that Teligent, Inc. (NASDAQ:TLGT) will post $19.17 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Teligent’s earnings, with estimates ranging from $18.70 million to $19.90 million. Teligent posted sales of $16.15 million in the same quarter last year, which suggests a positive year over year growth rate of 18.7%. The firm is expected to report its next quarterly earnings report on Thursday, October 26th.
On average, analysts expect that Teligent will report full year sales of $19.17 million for the current financial year, with estimates ranging from $80.10 million to $80.90 million. For the next financial year, analysts anticipate that the business will report sales of $118.31 million per share, with estimates ranging from $109.58 million to $136.60 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Teligent.
Teligent (NASDAQ:TLGT) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.04). Teligent had a negative net margin of 11.36% and a positive return on equity of 1.49%. The company had revenue of $18.40 million for the quarter, compared to the consensus estimate of $20.11 million. During the same period last year, the firm posted $0.02 earnings per share. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year.
A number of brokerages recently weighed in on TLGT. Roth Capital set a $9.00 target price on shares of Teligent and gave the company a “buy” rating in a research note on Wednesday, August 23rd. Deutsche Bank AG lowered their target price on shares of Teligent from $9.00 to $8.00 and set a “hold” rating on the stock in a research note on Monday, August 14th. Canaccord Genuity reaffirmed a “buy” rating and issued a $11.00 target price on shares of Teligent in a research note on Tuesday, August 8th. BidaskClub cut shares of Teligent from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st. Finally, ValuEngine cut shares of Teligent from a “hold” rating to a “sell” rating in a research report on Tuesday, July 25th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $9.33.
Shares of Teligent (NASDAQ:TLGT) opened at 7.12 on Friday. The firm’s 50-day moving average is $6.90 and its 200-day moving average is $6.90. The company’s market capitalization is $380.14 million. Teligent has a 12-month low of $5.75 and a 12-month high of $7.99.
A number of hedge funds and other institutional investors have recently modified their holdings of TLGT. Teachers Advisors LLC grew its position in Teligent by 1.0% during the fourth quarter. Teachers Advisors LLC now owns 65,454 shares of the company’s stock valued at $433,000 after acquiring an additional 648 shares during the last quarter. Wells Fargo & Company MN grew its position in Teligent by 3.1% during the first quarter. Wells Fargo & Company MN now owns 45,617 shares of the company’s stock valued at $357,000 after acquiring an additional 1,369 shares during the last quarter. UBS Asset Management Americas Inc. bought a new position in Teligent during the first quarter valued at approximately $170,000. Raymond James Financial Services Advisors Inc. grew its position in Teligent by 19.7% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 48,030 shares of the company’s stock valued at $375,000 after acquiring an additional 7,897 shares during the last quarter. Finally, American International Group Inc. grew its position in Teligent by 7.1% during the first quarter. American International Group Inc. now owns 25,488 shares of the company’s stock valued at $199,000 after acquiring an additional 1,680 shares during the last quarter. Institutional investors and hedge funds own 66.00% of the company’s stock.
Teligent Company Profile
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.